QR kód

Prognostic factors for patients treated with abiraterone

Aim: To evaluate prostate-specific antigen response (PSAr) defined as a ≥50% decrease in PSA concentration from the pretreatment value, as a prognostic factor in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). Methods: Retrospective evalua...

Celý popis

Uloženo v:
Hlavní autoři: Cecília M Alvim, André Mansinho, Rita S Paiva, Raquel Brás, Patrícia M Semedo, Soraia Lobo-Martins, Carolina B da Ponte, Daniela Macedo, Leonor Ribeiro, José P dos Reis, Isabel Fernandes, Luís Costa
Médium: Artigo
Jazyk:Inglês
Vydáno: Taylor & Francis Group 2020-02-01
Edice:Future Science OA
Témata:
abiraterone acetate
metastatic castration-resistant prostate cancer
prostate-specific antigen response
On-line přístup:https://www.future-science.com/doi/10.2144/fsoa-2019-0079
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky